These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16446155)

  • 21. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
    Masetti M; Cavalli A; Recanatini M
    J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of sophocarpine on HERG K+ channels].
    Qi ZP; Shi SS; Zhao XL; Zhao WX; Bai YL; Lü YJ; Li BX; Yang BF
    Yao Xue Xue Bao; 2008 Jan; 43(1):44-9. PubMed ID: 18357730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
    Imai YN; Ryu S; Oiki S
    J Med Chem; 2009 Mar; 52(6):1630-8. PubMed ID: 19260734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C.
    Guo J; Zhan S; Lees-Miller JP; Teng G; Duff HJ
    Heart Rhythm; 2005 Aug; 2(8):860-6. PubMed ID: 16051125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-go-Related Gene K + Channel by Tolterodine.
    Wang N; Yang Y; Wen J; Fan XR; Li J; Xiong B; Zhang J; Zeng B; Shen JW; Chen GL
    J Cardiovasc Pharmacol; 2022 Nov; 80(5):679-689. PubMed ID: 35881423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channels.
    Twiner MJ; Doucette GJ; Rasky A; Huang XP; Roth BL; Sanguinetti MC
    Chem Res Toxicol; 2012 Sep; 25(9):1975-84. PubMed ID: 22856456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed HERG currents in Xenopus oocytes.
    Kim CS; Lee N; Son SJ; Lee KS; Kim HS; Kwak YG; Chae SW; Lee SD; Jeon BH; Park JB
    Acta Pharmacol Sin; 2007 Apr; 28(4):503-10. PubMed ID: 17376289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation by testosterone of an endogenous hERG potassium channel current.
    Ridley JM; Shuba YM; James AF; Hancox JC
    J Physiol Pharmacol; 2008 Sep; 59(3):395-407. PubMed ID: 18953086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine.
    Kim MD; Eun SY; Jo SH
    Eur J Pharmacol; 2006 Aug; 544(1-3):82-90. PubMed ID: 16860311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
    Hancox JC; James AF
    Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamics and continuum electrostatics studies of inactivation in the HERG potassium channel.
    Kutteh R; Vandenberg JI; Kuyucak S
    J Phys Chem B; 2007 Feb; 111(5):1090-8. PubMed ID: 17266262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels.
    Yoshida K; Niwa T
    J Chem Inf Model; 2006; 46(3):1371-8. PubMed ID: 16711756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive in silico modeling for hERG channel blockers.
    Aronov AM
    Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel hypothesis for the binding mode of HERG channel blockers.
    Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
    Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method.
    Shin DS; Park MJ; Lee HA; Lee JY; Chung HC; Yoo DS; Chae CH; Park SJ; Kim KS; Bae MA
    Toxicol Appl Pharmacol; 2014 Feb; 274(3):361-71. PubMed ID: 24374264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythromycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
    Chen SZ; Zhang SH; Gong JH; Zhen YS
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(47):3353-7. PubMed ID: 17313833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.